NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that physicians at the Mayo Clinic in Jacksonville, Florida, have reported positive outcomes from a large cohort of epilepsy patients treated with the OneRF Ablation System. The real-world evidence suggests a potential paradigm shift in the treatment of drug-resistant focal epilepsy, combining diagnosis and therapy through a single implanted electrode system.
Led by neurologist Dr. Brin Freund and the late neurosurgeon Dr. Sanjeet Grewal, the team performed radiofrequency (RF) ablations on 25 patients with drug-resistant focal epilepsy. After diagnostic stereo-EEG (SEEG) monitoring with NeuroOne electrodes, physicians evaluated each patient's seizure foci to determine the safety of RF ablation. All patients were deemed appropriate candidates based on their anatomy and seizure localization.
The physicians reported that among the 25 evaluable patients, the procedure was well tolerated, with rare short-term effects and no serious long-term complications. The majority of patients experienced meaningful reductions in seizure frequency, while some achieved sustained seizure freedom either directly after RF ablation or after subsequent surgical or medical therapy guided by ablation data. Most patients also reported improved quality of life and satisfaction with the procedure. Ablation targets ranged from small, discrete seizure areas to multifocal or more extensively distributed epileptic networks.
Dr. Freund commented, “NeuroOne SEEG-guided radiofrequency thermocoagulation is a minimally invasive procedure that can be performed at the bedside through the same implanted diagnostic electrodes used to localize a patient's seizures. After recording seizures and mapping critical brain regions, we can precisely target seizure-generating tissue while preserving normal brain function. An important advantage is its ability to deliver controlled, temperature-based treatment while allowing us to immediately resume recording afterward. This enables real-time assessment of ablation effectiveness and, when appropriate, additional targeted ablations during the same monitoring period. This approach has changed how we treat drug-resistant focal epilepsy and is now part of the standard of care at Mayo Clinic Florida.”
Dave Rosa, CEO of NeuroOne, stated, “These results validate our long-held belief that, for patients already undergoing diagnostic SEEG, the ability to deliver meaningful therapeutic benefit through the same implanted electrodes represents a compelling clinical and economic value proposition. That opportunity is enabled by our proprietary temperature monitoring technology, which provides real-time treatment feedback and an additional layer of confidence during ablation. As the only FDA-cleared platform combining SEEG diagnosis and RF ablation using the same sEEG device, we believe NeuroOne is uniquely positioned to support this evolving diagnosis-to-therapy treatment paradigm.”
This news matters for leaders in business and technology because it highlights a shift toward minimally invasive, cost-effective treatments that combine diagnostic and therapeutic capabilities. For the epilepsy community, it offers hope for improved outcomes with fewer procedures. For the medical device industry, NeuroOne's integrated platform could set a new standard, potentially reducing hospitalizations and lowering healthcare costs. The real-world evidence from a respected institution like Mayo Clinic strengthens the case for wider adoption of this technology.
For more information about NeuroOne and its technology, visit nmtc1.com.
